Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUSTO trial of gene expression subtype-guided treatment for muscle-invasive bladder cancer
ISRCTN17378733Phase 2Active, not recruiting
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Aug 2023
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of durvalumab, tremelimumab, cisplatin and gemcitabine in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoints: Recruitment in first 6 months, Time to return of gene expression subtype allocation and 6 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
durvalumabtremelimumabcisplatingemcitabine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN17378733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17378733.